CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
癌症 CAR-T 细胞治疗：反应评估的更新与挑战
英文原题：CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment.
查看英文原题
CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法改变了多种血液系统恶性肿瘤的治疗格局，在部分病例中显示明确的治愈潜力。自2017年以来，已有7种CAR-T 细胞产品获得美国食品药品监督管理局（FDA）适应证批准，相关研究仍在持续推进，旨在提高CAR-T 疗效，同时减少副作用和复发风险。核医学在这一优化过程中发挥了关键作用，可用于初始分期、疗效评估和不良反应监测。本综述介绍CAR-T 细胞疗法，并重点阐述肿瘤患者照护中核医学的金标准实践及影像技术创新。此外，随着该领域的发展，持续推动医学影像创新也十分必要。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape for multiple hematologic malignancies, demonstrating a clear curative potential in select cases. Since 2017, 7 CAR T-cell products have indications approved by the Food and Drug Administration, and research is continuously evolving with the intent of enhancing CAR T-cell efficacy while reducing side effects and the risk of relapse.
Nuclear medicine has played a crucial role throughout this optimization process, assisting initial staging, treatment response assessment, and adverse-effect monitoring. This review provides an introduction to CAR T-cell therapy and highlights gold-standard nuclear medicine practices and imaging innovations for use in the care of oncology patients.
Additionally, it emphasizes the need for continuing innovation in medical imaging as the field progresses.
论文信息
- 作者
- de Jong D、McGale JP、Robinson TJ、Liao MJ、Das JP、Major A、Capaccione KM、Ladbury C
- 第一作者单位
- RefleXion Medical, Hayward, California; laurent.dercle@gmail.com ddejong990@gmail.com.
- 通讯作者单位
- Department of Radiology, New York-Presbyterian/Columbia University Irving Medical Center, New York, New York; laurent.dercle@gmail.com ddejong990@gmail.com.United States
- 文献类型
- 综述
- 期刊
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine2026 Jul 1
- 原文标识
- PubMed 42386374 · DOI 10.2967/jnumed.123.266605